放化疗综合治疗非霍奇金淋巴瘤远期疗效

Treatment of Non - Hodgkin's Lymphomas with Combined Radio-Chemotherapy

作者对72例NHL的治疗方法与预后的关系进行临床探讨。本组结外NHL居多占70．8％，Ⅲ、Ⅳ期病人占45．8％。所有病例均经病理证实。其中22例接受扩大野放射治疗（R组）；50例接受放化疗综合治疗（RC）组。全组3、5、10、15和＞18年生存率分别为61．1％、54．0％、43．8％、35．0％和31．3％。其中R组3、5、10、15和18年以上生存率分别为59．1％、53．2％、23．3％、11．1％和（0／5）；RC组分别为61．4％、57．7％、53．2％、41．1％和38．3％。尽管RC组病情较R组严重，但其各年生存率均高于R组，尤以10年以上生存差别显著。初步结果显示放化疗综合治疗NHL是提高远期生存率的有效方法之一。

Theraputic result of 72 patients with non Hodgkin's lymphomas (NHL) are evaluated. 70.8% of the cases were out of the lymph nodes, 45.8% at Ⅲ、Ⅳstage. Allpathologically comfirmed. 22 patients received extansion field radiotherapy (R); 50 pa-tients received radiotherapy combined with chemotherapy (RC). The overall survivalrates of 3、5、10、15 and>18yean were 61.1 %、54.0%、43.8%、35.0% 、and 31.3%， respectively. the 3、5 、10、15 and >18 year survival rates were 59.1%、53.2%、23.3%、11.l% and (0/5)in R group; 61.4% 、57.7% 、53.2% 、41.1% and 38.3% in RC group，re-spectively. Although the condition of the patients in RC group was more severe than Rgroup, The long term survival rates in RC group were higher than those in R group.The preliminary results shown that radiotherapy combined with chemotherapy is moreeffective in improving long term survival rates for NHL than radiotherapy alone.